裵埈範（BAE JUNBOM）先生，1970 年 5 月出生，韩国国籍，庆熙大学电子 工程学士。历任现代电子（现 SK 海力士）光学处理工程师，科莱恩韩国 IC 芯片 销售及技术支持，科莱恩 193nm 光刻胶项目组成员、研发部成员，安智韩国平板 显示器销售经理，安智中国新业务发展经理-FPD 及半导体、面板/光电市场部经 理，默克中国光刻胶市场部经理/面板项目部经理，默克韩国半导体项目国际 QA 专家，易美太公司研发部/首席研究员；2023 年 7 月，就职于公司，现任天津久 证券代码：688199 证券简称：久日新材 公告编号：2023-048 1 天津久日新材料股份有限公司 日半导体材料有限公司 QA&QC 总监。 关于新增认定核心技术人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 天津久日新材料股份有限公司（以下简称公司）为进一步提升在半导体化学 材料领域的创新能力和技术水平，加强研发团队实力，确保技术升级和研发目标 的实现，现根据公司实际情况并经管理层研究，结合任职履历、未来对公司研发 项目和业务发展 ...

Financial Performance - In 2022, the company achieved operating revenue of CNY 1,410,958,551.74, an increase of 12.66% year-on-year[4]. - The net profit attributable to shareholders was CNY 43,347,271.78, a decrease of 73.83% compared to the previous year[4]. - The company will not distribute profits for the 2022 fiscal year, opting to retain earnings for future investments and operational needs[13]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[28]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[28]. - The basic earnings per share fell by 73.86% to ¥0.40, down from ¥1.53 in 2021[30]. - The net profit attributable to shareholders after excluding non-recurring gains and losses was approximately ¥16.22 million, down 87.14% from ¥126.17 million in 2021[29]. - The company achieved a revenue of CNY 1,410,958,551.74 in 2022, representing a year-on-year increase of 12.66%[41]. - The net profit attributable to shareholders was CNY 43,347,271.78, a year-on-year decrease of 73.83%[41]. - The company reported a significant drop in sales volume of light initiators due to a weak end market, impacting overall performance[31]. Production Capacity and Expansion - The company has expanded its production capacity with the commissioning of a project in Inner Mongolia, which has an annual capacity of 9,250 tons of photoinitiators and intermediates[5]. - The company has established multiple modern production bases for photopolymer materials, including locations in Shandong, Hunan, Jiangsu, and Inner Mongolia[5]. - The company has initiated a project for producing 600 tons of photoresist-specific photoinitiators, which began trial production in October 2022[6]. - The company plans to strengthen its semiconductor chemical materials sector by advancing the planning and construction of a semiconductor photoresist production base[7]. - The company is investing in new production bases to enhance production capacity and meet growing market demands[51]. - The company has developed a large-scale production process for photoinitiators, demonstrating strong independent R&D capabilities[94]. - The company has optimized production processes and updated equipment at its Hunan and Shandong bases, improving production efficiency[44]. - The company has achieved a substantial increase in production capacity through the automation of traditional synthesis processes for photo-initiators 1173 and 184[71]. Research and Development - The company added 52 new patents during the reporting period, including 25 invention patents and 27 utility model patents, enhancing its innovation capabilities[42]. - Research and development expenses accounted for 5.99% of operating revenue, slightly up from 5.65% in 2021[30]. - The total R&D investment for the year was ¥84,524,096.49, representing a 19.45% increase compared to the previous year[79]. - The company has established a national enterprise technology center and a national postdoctoral research station, enhancing its R&D capabilities[91]. - The company is focusing on environmental innovation processes in its photoinitiator production, improving energy efficiency and sustainability[75]. - The company has developed new core technologies including "photo-sensitizer production technology" and "panel photoresist formulation technology" during the reporting period[69]. - The company is focusing on continuous innovation in new products and technologies, which is a core competitive advantage[90]. - The company has developed innovative production processes for its core products, significantly reducing raw material consumption and waste generation while enhancing safety[184]. Market Strategy and Challenges - The company continues to face challenges due to a significant decline in market demand and has implemented pricing strategies to maintain market share[11]. - The company aims to become a global leader in photopolymer materials, focusing on innovation and expansion in both the photopolymer and semiconductor industries[7]. - The company adopted a sales discount strategy to maintain market share, which contributed to a decline in revenue and gross profit[31]. - The competitive landscape remains challenging, with potential further declines in sales volume and prices for photoinitiators due to ongoing geopolitical tensions and economic uncertainties[123]. - The company is exposed to exchange rate risks due to a significant portion of revenue coming from exports, which could affect foreign exchange gains and losses[106]. - The company faces risks related to the potential loss of core technical personnel, which is critical for maintaining competitive advantage[112]. - The company is focusing on enhancing its product offerings and technological advancements to drive future growth[132]. Environmental and Sustainability Efforts - The company aims to reduce VOC emissions by 15% in line with environmental regulations[28]. - The UV curing technology is recognized for its environmental benefits, efficiency, and cost-effectiveness, aligning with global sustainability trends[54]. - The company is positioned to benefit from favorable industry policies promoting the use of eco-friendly materials and technologies[57]. - The company’s focus on energy-saving and emission-reduction technologies is expected to receive substantial policy support under the national "dual carbon" goals[179]. - The feed-grade benzoic acid project is positioned as a beneficial project for public health, replacing antibiotics in animal feed and promoting food safety[168]. Acquisitions and Investments - The company acquired 100% equity of Huaihua Taitong, which produces key raw materials for its core photoinitiator products, ensuring stable supply[44]. - A strategic acquisition of a local competitor is anticipated to enhance production capacity by 30%[28]. - The company has invested in Tianjiao Radiation, holding a 38.46% stake, to enhance its product offerings in UV monomers[61]. - The company has completed the acquisition of Keli Biological and Jinghong Biological in June 2021, marking a significant step in the strategic layout of the photoresist and semiconductor materials field[172]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[28]. - The company expects a recovery in 2024, with projected revenue of 339.50 million yuan, returning to levels similar to 2021[200]. - The company anticipates a net profit of 15.58 million yuan in 2024, indicating a strong recovery[200]. - The company is focused on returning to normal operations by 2024, with all production expected to be fully restored[200].

关于参加 2022 年度半导体专场集体业绩说明会 暨现金分红说明会的公告 证券代码：688199 证券简称：久日新材 公告编号：2023-023 天津久日新材料股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 5 月 17 日（星期三）下午 14:00-16:00 会议召开方式：视频和线上文字互动 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 5 月 16 日（星期二）16:00 前通过邮件、电话等形 式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 天津久日新材料股份有限公司（以下简称公司）已于 2023 年 4 月 15 日发布 公司《2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况、发展理念及现金分红的具体情况，公司参与了由上 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥265,902,365.16, representing a decrease of 37.14% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥17,849,017.84, a decline of 132.59% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥24,293,284.17, reflecting a decrease of 151.03% compared to the previous year[4] - The net cash flow from operating activities was negative at ¥40,395,654.20, a decline of 207.85% year-over-year[4] - The company attributed the decline in revenue and profit to external market conditions and a decrease in sales prices of photoinitiators, despite a slight increase in sales volume[8] - Net profit for Q1 2023 was a loss of ¥20,798,143.39, compared to a profit of ¥60,206,842.13 in Q1 2022[18] - The company reported a gross profit margin of -5.4% in Q1 2023, compared to 14.0% in Q1 2022[17] - Operating profit for Q1 2023 was a loss of ¥12,368,402.33, compared to a loss of ¥473,781.76 in Q1 2022[30] - Net profit for Q1 2023 was a loss of ¥12,963,550.35, compared to a loss of ¥1,003,382.62 in Q1 2022, indicating a worsening financial performance[30] Research and Development - The total R&D investment amounted to ¥14,621,941.34, which is a decrease of 31.06% compared to the previous year[4] - R&D investment accounted for 5.50% of operating revenue, an increase of 0.49 percentage points year-over-year[5] - Research and development expenses for Q1 2023 were ¥14,621,941.34, a decrease of 30.8% from ¥21,208,575.74 in Q1 2022[17] - Research and development expenses decreased to ¥3,553,060.76 in Q1 2023 from ¥5,092,449.04 in Q1 2022, reflecting a 30.3% reduction[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,063,682,545.30, a decrease of 1.03% from the end of the previous year[5] - The company's total assets amounted to CNY 4,063,682,545.30, a decrease from CNY 4,105,789,706.50 at the end of 2022, reflecting a decline of approximately 1.02%[13] - The total current assets decreased to CNY 1,825,154,911.49 from CNY 1,896,250,492.13, indicating a reduction of approximately 3.73%[14] - The company's total liabilities increased to CNY 1,800,000,000.00, reflecting a rise in financial obligations[14] - The company's total liabilities decreased to ¥1,255,835,304.83 in Q1 2023 from ¥1,279,229,157.38 in Q1 2022[16] - Total liabilities reached CNY 1.28 billion, with current liabilities at CNY 930.55 million and non-current liabilities at CNY 348.68 million[38] - The company's total liabilities increased to 472,416,697.09 RMB from 446,077,648.21 RMB, indicating a rise in financial obligations[26] Cash Flow - The net cash flow from operating activities was -40,395,654.20 RMB, a significant decline compared to 37,454,291.96 RMB in the previous year, indicating a negative cash flow trend[22] - Cash flow from operating activities was ¥224,371,631.59 in Q1 2023, down 39.0% from ¥367,953,548.42 in Q1 2022[21] - The net cash flow from financing activities was 73,535,817.62 RMB, down from 148,878,918.15 RMB in the previous year, suggesting a decrease in financing efficiency[23] - The cash flow from investment activities showed a net increase of 60,626,737.18 RMB, a significant improvement from a net outflow of -244,329,279.32 RMB in the previous year[22] - The company achieved cash inflow from investment activities of ¥760,122,843.38 in Q1 2023, compared to ¥284,208,949.98 in Q1 2022[32] Shareholder Information - The number of shares held by the top shareholder, Zhao Guofeng, is 19,771,609, representing 17.78% of the total shares[12] - The company has a share repurchase account holding 2,821,248 shares, accounting for 2.54% of the total share capital[12] - The total equity attributable to shareholders was ¥2,706,190,529.17 in Q1 2023, slightly down from ¥2,722,303,782.74 in Q1 2022[16] - Shareholders' equity totaled CNY 2.83 billion, with retained earnings of CNY 599.70 million[39] Inventory and Current Assets - Inventory levels decreased to CNY 328,494,119.38 from CNY 376,395,490.72, showing a decline of about 12.74%[14] - The company's receivables from accounts increased to CNY 206,480,187.18 from CNY 188,958,277.39, marking a rise of about 9.43%[13] - The company's total current assets were 1,681,516,241.08 RMB, slightly up from 1,672,370,769.20 RMB year-over-year, indicating stable asset management[24] Financial Ratios and Metrics - The weighted average return on net assets was -0.66%, a decrease of 2.64 percentage points compared to the previous year[4] - Basic and diluted earnings per share for Q1 2023 were both -¥0.16, compared to ¥0.51 in Q1 2022[19] - The company reported an investment loss of ¥419,077.07 in Q1 2023, compared to a profit of ¥8,523,345.98 in Q1 2022[18] - The company's financial expenses showed a significant improvement, with a net financial expense of -¥103,604.00 in Q1 2023 compared to ¥1,809,197.88 in Q1 2022[28]

Financial Performance - In 2022, the company achieved operating revenue of CNY 1,410,958,551.74, an increase of 12.66% year-on-year[4] - The net profit attributable to shareholders was CNY 43,347,271.78, a decrease of 73.83% year-on-year[4] - The company's operating revenue for 2022 was approximately ¥1.41 billion, representing a 12.66% increase compared to ¥1.25 billion in 2021[29] - The net profit attributable to shareholders decreased by 73.83% to approximately ¥43.35 million from ¥165.66 million in 2021[29] - The basic earnings per share dropped by 73.86% to ¥0.40 from ¥1.53 in the previous year[30] - The net cash flow from operating activities increased by 97.21% to approximately ¥144.06 million, driven by higher cash receipts from sales and increased tax refunds[31] - The total assets at the end of 2022 were approximately ¥4.11 billion, a 6.29% increase from ¥3.86 billion at the end of 2021[29] - The weighted average return on equity decreased to 1.59% from 6.24% in 2021, indicating a significant decline in profitability[30] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 87.14% to approximately ¥16.22 million from ¥126.17 million in 2021[29] - The company's gross profit margin decreased by 9.03 percentage points, with a gross profit margin of 18.52%[123] Production and Capacity Expansion - The company expanded its production capacity with the launch of a project in Inner Mongolia, targeting an annual output of 9,250 tons of photoinitiators and intermediates[5] - The company initiated a project for a microelectronics photoinitiator with an annual capacity of 600 tons, which began trial production in October 2022[6] - The company has established multiple production bases to ensure stable supply and customer demand for key photoinitiator products, including 184, TPO, and 1173[51] - The company is investing in new production lines to increase the value of its products, such as the feed-grade benzoic acid production line[165] - The company has built modern production bases in Shandong, Jiangsu, Hunan, and Inner Mongolia, enhancing its supply stability and capacity[96] Research and Development - The company added 52 new authorized patents during the reporting period, including 25 invention patents and 27 utility model patents, enhancing its innovation capabilities[42] - Research and development investments increased by 40%, totaling RMB 100 million, focusing on advanced photoinitiators[21] - The total R&D investment for the year was approximately ¥84.52 million, representing a 19.45% increase from the previous year's ¥70.76 million[79] - R&D investment accounted for 5.99% of total revenue, an increase of 0.34 percentage points compared to the previous year[79] - The company has established a strong R&D foundation with 136 patents, including 89 invention patents[91] - The company is focusing on sustainable development through the improvement of waste treatment processes in its production operations[75] Market Strategy and Challenges - The company aims to maintain its market share by implementing sales strategies, including price reductions, despite the impact on revenue and profit margins[11] - The company has faced challenges due to a significant decline in market demand, leading to a reduction in sales volume of photoinitiators compared to the previous year[11] - The company is actively expanding its market presence and enhancing its competitive advantage through strategic acquisitions and new product development[96] - The company is facing risks of continued performance decline if external market conditions do not improve, despite a gradual recovery in the industry[101] - The company is exposed to foreign exchange risks, particularly with fluctuations in the RMB to USD exchange rate affecting export revenues[106] Environmental and Regulatory Factors - The demand for UV-curable products is expected to increase due to stricter environmental regulations and consumer preferences for safer products[57] - The company is well-positioned to benefit from favorable policies related to energy conservation and emissions reduction in the context of the national "dual carbon" goals[150] - The company has implemented innovative production processes that significantly reduce raw material consumption and waste generation, achieving near-zero wastewater production[155] Acquisitions and Investments - The company acquired 100% equity of Huaihua Taitong, which produces key raw materials for its core photoinitiator products, ensuring stable supply[44] - The company made significant acquisitions, including Hunan Jiuri's purchase of Hongrun Chemical and Huaihua Taitong, contributing to revenue growth[120] - The company plans to invest an additional 31,332.02 million RMB in the Inner Mongolia Jiuri project, increasing the total investment from 55,045.70 million RMB to 86,377.72 million RMB[181] Product Development and Innovation - The company is focused on continuous product development and expanding application areas to drive future growth[56] - The company has developed new core technologies including "photo-sensitizer production technology" and "panel photoresist formulation technology" during the reporting period[69] - The company has successfully developed new photoinitiators tailored for specific applications, enhancing its product offerings[156] Financial Management and Performance Metrics - The company has implemented measures to mitigate production stoppages due to environmental and safety regulations, but risks remain from external factors[111] - The company has experienced a significant decrease in financial expenses by 71.90%, mainly due to exchange rate fluctuations[137] - The company's cash flow from financing activities was CNY 153,278,949.19, compared to a negative cash flow of CNY -50,343,272.44 in the previous year, indicating a significant improvement[138]

2022 年第三季度报告 一、 主要财务数据 （一）主要会计数据和财务指标 证券代码：688199 证券简称：久日新材 天津久日新材料股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 294,205,168.22 | 10.79 | 1,111,657,404.72 | 24.3 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 20% year-over-year growth[13]. - The company's operating revenue for the first half of 2022 was approximately ¥817.45 million, an increase of 30.02% compared to ¥628.70 million in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥99.88 million, representing a 19.38% increase from ¥83.66 million in the previous year[20]. - The basic earnings per share for the first half of 2022 was ¥0.92, up 19.48% from ¥0.77 in the same period last year[19]. - The net cash flow from operating activities increased by 88.56% to approximately ¥130.72 million, compared to ¥69.33 million in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 47.03% to approximately ¥83.67 million, compared to ¥56.91 million in the same period last year[20]. - The company's total assets as of the end of the reporting period were approximately ¥4.40 billion, a 13.80% increase from ¥3.86 billion at the end of the previous year[20]. - The company has maintained a strong cash position, with cash reserves amounting to 200 million RMB, ensuring liquidity for future investments[13]. Research and Development - The company is investing 30 million RMB in R&D for new technologies aimed at improving production efficiency by 15%[13]. - The company's R&D investment accounted for 5.59% of operating revenue, an increase of 0.22 percentage points from the previous year[19]. - The company achieved a total R&D investment of ¥45,659,094.27, representing a 35.16% increase compared to ¥33,780,917.25 in the same period last year[58]. - The company added 39 new authorized patents during the reporting period, including 15 invention patents and 24 utility model patents, enhancing its innovation capabilities[76]. - The company holds 123 patents, including 79 invention patents and 44 utility model patents, and has participated in the formulation of 9 industry standards[67]. - The company has a strong focus on R&D, holding 79 invention patents and 44 utility model patents, enhancing its innovation capabilities[32]. - The company is actively exploring new product developments, including high-performance UV monomers and low-odor photoinitiators, to cater to diverse customer needs[34]. Market Expansion and Strategy - The company is expanding its market presence, targeting new regions in Southeast Asia, with an investment of 50 million RMB allocated for market entry strategies[13]. - A strategic acquisition of a local competitor is in progress, which is projected to enhance market share by 10%[13]. - The company has acquired subsidiaries Hunan Jiuri and Hongrun Chemical, contributing to the increase in consolidated revenue[20]. - The company is adapting to market demands by developing customized photoinitiators that meet the specific needs of downstream customers[41]. - The company is focusing on the development of UV LED photoinitiators suitable for light-colored inks and wood coatings, which are characterized by excellent performance and cost-effectiveness[53]. - The company is expanding its market presence through strategic acquisitions and investments in new technologies and products[116]. Environmental Compliance and Sustainability - The company has implemented various pollution prevention measures, including clean production and wastewater separation systems, to reduce pollutant emissions[129]. - The company has established emergency response plans for environmental incidents to prevent soil contamination[129]. - The company has optimized its VOCs emission treatment systems, including RTO incineration systems, to ensure compliance with emission standards[130]. - The company’s wastewater treatment systems, including physical and biological treatment, are operating normally and meet discharge standards[130]. - The company has implemented strict compliance with environmental laws and regulations across all operational sites[131]. - The company has invested significantly in environmental protection facilities and technology improvements to comply with environmental regulations, which may increase operational costs if stricter regulations are implemented in the future[86]. Risk Management - The management highlighted potential risks, including supply chain disruptions that could impact production capacity by up to 20%[4]. - The company faces risks related to core competitiveness, operational management, and industry competition due to rapid market changes[79][80][81]. - The company faces risks related to the loss of core technical personnel, which could negatively impact operational performance if competitive compensation and incentives are not maintained[89]. - The ongoing impact of the COVID-19 pandemic continues to create uncertainty in demand due to inflation and geopolitical factors[92]. - The company has encountered risks related to the implementation of fundraising investment projects, which are crucial for enhancing competitiveness but face market uncertainties[93]. Shareholder Commitments and Governance - The company commits to strict compliance with laws and regulations to ensure effective governance and protect minority shareholders' rights[184]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders, ensuring accountability for any losses incurred[192]. - The company will not engage in unfair practices that harm its interests or those of its shareholders[187]. - The company will adhere to a profit distribution policy as outlined in its articles of association and future shareholder return plans[188]. - The company publicly apologized to shareholders and investors for not fulfilling commitments during the shareholder meeting and on designated media[196].

Financial Performance - The company's operating revenue for 2021 was CNY 1,252,459,155.24, representing a 23.83% increase compared to CNY 1,011,418,016.27 in 2020[20]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 165,657,630.46, a 21.15% increase from CNY 136,742,721.34 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 42.45% to CNY 126,168,664.65 in 2021 from CNY 88,571,255.53 in 2020[22]. - The basic earnings per share for 2021 was CNY 1.53, up 24.39% from CNY 1.23 in 2020[21]. - The weighted average return on net assets increased to 6.24% in 2021, up from 5.12% in 2020, an increase of 1.12 percentage points[21]. - The company's cash flow from operating activities decreased by 61.75% to CNY 73,047,039.44 in 2021, compared to CNY 190,983,693.21 in 2020, primarily due to increased inventory purchases[22]. - The total assets of the company at the end of 2021 were CNY 3,862,740,277.63, a 16.94% increase from CNY 3,303,224,167.49 at the end of 2020[20]. - The company's total revenue for the reporting period reached ¥1,252,096,211.03, with a gross margin of 27.55%, an increase of 2.28 percentage points compared to the previous year[114]. - The export revenue amounted to ¥657,689,910.03, showing a year-on-year increase of 41.41%, driven by improved sales channels and recovering demand in international markets[116]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 54,202,776.00, which represents 61.49% of the net profit attributable to shareholders for the year[5]. - As of March 31, 2022, the total share capital of the company is 111,226,800 shares, with 2,821,248 shares held in the repurchase account not participating in the dividend distribution[5]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not faced any violations in decision-making procedures for external guarantees[7]. - The company has not disclosed any special arrangements for corporate governance[7]. - The company emphasizes the importance of maintaining a robust governance structure to ensure compliance and effective decision-making[188]. - The company maintains strict independence from its controlling shareholder, with independent operations in business and finance, ensuring no fund misappropriation issues[190]. - The fourth board of directors consists of 9 members, including 3 independent directors, complying with legal requirements for governance[191]. - The fourth supervisory board is composed of 3 members, including 1 employee supervisor, ensuring compliance with legal standards[192]. - The company has established comprehensive management systems, including revised internal control and financial management regulations, enhancing governance[193]. - The company has implemented an information disclosure management system to ensure the accuracy and timeliness of disclosures, in line with regulatory requirements[194]. - There are no significant discrepancies between the company's governance practices and regulatory requirements, ensuring compliance[196]. Research and Development - The company has a strong R&D capability with numerous patents and a mature system for converting research results into products[38]. - The company achieved a total R&D investment of ¥70,763,679.66, representing a 35.71% increase compared to the previous year[66]. - R&D investment accounted for 5.65% of total revenue, an increase of 0.49 percentage points from the previous year[66]. - The company holds a total of 84 patents, including 64 invention patents and 20 utility model patents, reflecting strong R&D capabilities[79]. - The company has developed new production processes for photoinitiators, improving efficiency and reducing environmental impact[62]. - The company is focusing on developing new products and technologies, including UV LED photoinitiators suitable for light-colored inks[62]. - The company has established multiple research centers and received various innovation awards during the reporting period[63]. - The company is focusing on developing new photoinitiators and specialty UV curing materials, although it faces challenges in innovation and market demand fluctuations[87]. Market Position and Strategy - The company is the largest and most comprehensive supplier of photoinitiators in China, with a significant global influence in the UV curing field[37]. - The company is focusing on the core industry of photopolymerization and expanding into the semiconductor sector, aiming for global market development[30]. - The company is actively extending its photopolymerization industry chain and expanding into electronic chemical materials[30]. - The company is committed to enhancing its core competitiveness through independent innovation and technology development[32]. - The company has established a strategic direction centered on the photopolymerization industry and semiconductor industry, aiming for global market expansion[182]. - The company is positioned to benefit from favorable policies related to carbon reduction goals, enhancing the market penetration of its photoinitiator products[143]. Risks and Challenges - The company emphasizes the importance of risk factors in its operations, advising investors to pay attention to potential risks[4]. - The company faces risks from intensified industry competition and potential price declines, despite its stable product quality and customer loyalty[90]. - The company faces exchange rate risks due to a significant portion of its revenue coming from exports, which may be impacted by fluctuations in the RMB to USD exchange rate[91]. - The company is experiencing increased operational management pressure due to rapid growth and expansion, necessitating improvements in its management systems[89]. - The ongoing COVID-19 pandemic continues to pose risks to the company's export business, particularly in countries with poor pandemic control[99]. Investments and Acquisitions - The company acquired 40% of Hongrun Chemical's shares, increasing its stake to 52%, making it a controlling subsidiary[35]. - The company is expanding its semiconductor electronic chemical materials business through acquisitions, including Jinghong Bio and Keli Bio, and introducing strategic investors[34]. - The company plans to acquire 100% equity of Huaihua Taitong, with the acquisition process currently underway[168]. - The company has established a wholly-owned subsidiary, Jiuxing Zhihui, with a registered capital of RMB 10 million for environmental-friendly radiation curing coating projects[169]. - The company acquired 100% equity of Jinghong Biological for RMB 9 million, focusing on electronic chemical materials[169]. Production and Supply Chain - The company has developed new production processes for key products like 1173 and 184, significantly reducing raw material consumption and waste generation[148]. - The company has optimized production lines for its main products, achieving a continuous production process that minimizes hazardous chemical use and waste emissions[158]. - The company has established multiple modern production bases to ensure stable supply of core photoinitiators like 184, TPO, and DETX, enhancing its competitive advantage in the market[82]. - The company is focusing on optimizing its production processes to improve efficiency and reduce costs, while also addressing environmental concerns[184].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 422,988,893.15, representing a year-on-year increase of 35.84%[4] - The net profit attributable to shareholders was CNY 54,775,456.06, reflecting a growth of 43.22% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 81.57% to CNY 47,604,110.91[4] - Basic and diluted earnings per share were both CNY 0.51, marking a 50.00% increase from the previous year[4] - Net profit for Q1 2022 was ¥60,206,842.13, up 57.5% from ¥38,218,112.15 in Q1 2021[20] - Operating profit for Q1 2022 was ¥73,406,666.63, representing a 59.1% increase compared to ¥46,135,361.21 in Q1 2021[20] - The company reported a total comprehensive income of ¥55,065,668.79 for Q1 2022, compared to ¥37,729,683.16 in Q1 2021[21] Cash Flow - The net cash flow from operating activities reached CNY 37,454,291.96, a significant increase of 1,018.99% year-on-year[4] - In Q1 2022, the cash inflow from operating activities was CNY 392,723,047.60, a 60% increase from CNY 245,289,422.04 in Q1 2021[23] - The net cash flow from operating activities reached CNY 37,454,291.96, compared to CNY 3,347,151.62 in the same period last year, indicating significant improvement[24] - The total cash outflow from investing activities was CNY 709,559,382.35, up from CNY 486,423,258.31 in Q1 2021, resulting in a net cash outflow of CNY 244,329,279.32[24] - The cash inflow from financing activities was CNY 254,143,747.32, compared to CNY 86,205,179.02 in Q1 2021, showing a substantial increase[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,093,240,885.23, up 5.97% from the end of the previous year[5] - The company's current assets totaled RMB 2,214,390,862.45, compared to RMB 2,082,661,951.33 at the end of 2021, indicating an increase of about 6.34%[17] - The total liabilities as of Q1 2022 amounted to ¥1,197,871,927.27, compared to ¥1,024,363,104.63 in Q1 2021, reflecting a 16.9% increase[19] - The company's total liabilities increased to CNY 514,067,191.69 from CNY 485,965,717.47 at the end of 2021[27] - The total equity decreased to CNY 2,576,076,531.22 from CNY 2,582,186,339.85 at the end of 2021[28] Research and Development - Research and development expenses amounted to CNY 21,208,575.74, accounting for 5.01% of operating revenue, a decrease of 0.46 percentage points[5] - Research and development expenses for Q1 2022 totaled ¥21,208,575.74, an increase from ¥17,031,304.12 in Q1 2021[19] - Research and development expenses increased to ¥5,092,449.04 in Q1 2022, up 37.8% from ¥3,696,077.63 in Q1 2021[30] Subsidiaries and Investments - The company’s subsidiary, Hunan Jiuri, contributed to revenue growth following the acquisition of Hongrun Chemical at the end of 2021[9] - The company’s subsidiary, Inner Mongolia Jiuri New Materials Co., Ltd., has commenced production for a new project with an annual capacity of 9,250 tons of photoinitiators and intermediates, which began trial operations on March 15, 2022[15] - The company reported a significant increase in trading financial assets, which rose to RMB 341,343,692.70 from RMB 100,290,000.00, indicating a growth of approximately 240.5%[16] - The company’s long-term equity investments increased slightly to RMB 122,947,518.86 from RMB 122,444,752.95, reflecting a growth of about 0.41%[17] - The company’s investment income for Q1 2022 was ¥4,174,626.19, a significant drop from ¥192,625,232.09 in Q1 2021[30]

2021 年第三季度报告 证券代码：688199 证券简称：久日新材 天津久日新材料股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 265,545,777.90 | 18.12 | 894,241,003.36 | 26.40 | | 归属于上市公司股东的 | 24,487,373.90 | -37.10 | 108,146,877.61 | -5.23 | | 净利润 | ...